# Airship AI Holdings, Inc.: financial statements, quarterly

AISP · Nasdaq · CIK 1842566 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/aisp.md) · [Financials](/companies/aisp/financials.md) · [Filings](/companies/aisp/filings.md) · [Insiders](/companies/aisp/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/aisp/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [2.4](/filings/0001654954-24-014445.md) | [4.2 d](/filings/0001654954-25-002153.md) | [10.6](/filings/0001654954-25-005754.md) | [6.4](/filings/0001654954-25-009056.md) | [2.9](/filings/0001654954-25-013084.md) | [3.2 d](/filings/0001654954-26-001280.md) | [5.5](/filings/0001654954-26-004630.md) | [2.1](/filings/0001654954-26-007328.md) | [1.2](/filings/0001654954-25-013084.md) | [6.5 d](/filings/0001654954-26-001280.md) | [6.4](/filings/0001654954-26-004630.md) | [4.1](/filings/0001654954-26-007328.md) |
| Cost of revenue | $m | [0.8](/filings/0001654954-24-014445.md) | [2.5 d](/filings/0001654954-25-002153.md) | [7.9](/filings/0001654954-25-005754.md) | [1.9](/filings/0001654954-25-009056.md) | [0.7](/filings/0001654954-25-013084.md) | [2.0 d](/filings/0001654954-26-001280.md) | [3.3](/filings/0001654954-26-004630.md) | [0.6](/filings/0001654954-26-007328.md) | [0.6](/filings/0001654954-25-013084.md) | [3.2 d](/filings/0001654954-26-001280.md) | [3.2](/filings/0001654954-26-004630.md) | [1.0](/filings/0001654954-26-007328.md) |
| Gross profit | $m | [1.6](/filings/0001654954-24-014445.md) | [1.7 d](/filings/0001654954-25-002153.md) | [2.6](/filings/0001654954-25-005754.md) | [4.5](/filings/0001654954-25-009056.md) | [2.2](/filings/0001654954-25-013084.md) | [1.2 d](/filings/0001654954-26-001280.md) | [2.2](/filings/0001654954-26-004630.md) | [1.5](/filings/0001654954-26-007328.md) | [0.6](/filings/0001654954-25-013084.md) | [3.3 d](/filings/0001654954-26-001280.md) | [3.2](/filings/0001654954-26-004630.md) | [3.1](/filings/0001654954-26-007328.md) |
| Research and development | $m | [0.7](/filings/0001654954-24-014445.md) | [0.7 d](/filings/0001654954-25-002153.md) | [0.7](/filings/0001654954-25-005754.md) | [0.7](/filings/0001654954-25-009056.md) | [1.1](/filings/0001654954-25-013084.md) | [0.3 d](/filings/0001654954-26-001280.md) | [0.7](/filings/0001654954-26-004630.md) | [0.7](/filings/0001654954-26-007328.md) | [0.8](/filings/0001654954-25-013084.md) | [0.9 d](/filings/0001654954-26-001280.md) | [0.8](/filings/0001654954-26-004630.md) | [0.9](/filings/0001654954-26-007328.md) |
| Selling, general and administrative | $m | [2.1](/filings/0001654954-24-014445.md) | [1.6 d](/filings/0001654954-25-002153.md) | [3.3](/filings/0001654954-25-005754.md) | [2.8](/filings/0001654954-25-009056.md) | [2.7](/filings/0001654954-25-013084.md) | [2.4 d](/filings/0001654954-26-001280.md) | [3.2](/filings/0001654954-26-004630.md) | [2.8](/filings/0001654954-26-007328.md) | [2.7](/filings/0001654954-25-013084.md) | [3.1 d](/filings/0001654954-26-001280.md) | [3.9](/filings/0001654954-26-004630.md) | [3.7](/filings/0001654954-26-007328.md) |
| Operating income | $m | [(1.2)](/filings/0001654954-24-014445.md) | [(0.6) d](/filings/0001654954-25-002153.md) | [(1.4)](/filings/0001654954-25-005754.md) | [1.0](/filings/0001654954-25-009056.md) | [(1.6)](/filings/0001654954-25-013084.md) | [(1.5) d](/filings/0001654954-26-001280.md) | [(1.7)](/filings/0001654954-26-004630.md) | [(2.0)](/filings/0001654954-26-007328.md) | [(2.9)](/filings/0001654954-25-013084.md) | [(0.6) d](/filings/0001654954-26-001280.md) | [(1.6)](/filings/0001654954-26-004630.md) | [(1.5)](/filings/0001654954-26-007328.md) |
| Interest expense | $m | [0.0](/filings/0001654954-24-014445.md) | not reported | [0.0](/filings/0001654954-24-006298.md) | [0.4](/filings/0001654954-24-010635.md) | [0.1](/filings/0001654954-24-014445.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [0.0](/filings/0001654954-24-014445.md) | [0.0 d](/filings/0001654954-25-002153.md) | [0.0](/filings/0001654954-25-005754.md) | [0.0](/filings/0001654954-25-009056.md) | [0.0](/filings/0001654954-25-013084.md) | [0.0 d](/filings/0001654954-26-001280.md) | [0.0](/filings/0001654954-26-004630.md) | [0.0](/filings/0001654954-26-007328.md) | [0.0](/filings/0001654954-25-013084.md) | [0.0 d](/filings/0001654954-26-001280.md) | [0.0](/filings/0001654954-26-004630.md) | [0.0](/filings/0001654954-26-007328.md) |
| Net income | $m | [(1.7)](/filings/0001654954-24-014445.md) | [22.9 d](/filings/0001654954-24-004059.md) | [(32.0)](/filings/0001654954-25-013084.md) | [18.5](/filings/0001654954-25-013084.md) | [6.2](/filings/0001654954-25-013084.md) | [(50.2) d](/filings/0001654954-26-001280.md) | [23.7](/filings/0001654954-26-004630.md) | [(23.8)](/filings/0001654954-26-007328.md) | [6.4](/filings/0001654954-25-013084.md) | [23.0 d](/filings/0001654954-26-001280.md) | [(0.7)](/filings/0001654954-26-004630.md) | [(2.4)](/filings/0001654954-26-007328.md) |
| Diluted EPS | $ per share | [(0.07)](/filings/0001654954-24-014445.md) | not reported | [(1.40)](/filings/0001654954-25-005754.md) | [0.61](/filings/0001654954-25-009056.md) | [0.17](/filings/0001654954-25-013084.md) | not reported | [0.61](/filings/0001654954-26-004630.md) | [(0.75)](/filings/0001654954-26-007328.md) | [0.15](/filings/0001654954-25-013084.md) | not reported | [(0.02)](/filings/0001654954-26-004630.md) | [(0.07)](/filings/0001654954-26-007328.md) |
| Basic EPS | $ per share | [(0.07)](/filings/0001654954-24-014445.md) | not reported | [(1.40)](/filings/0001654954-25-005754.md) | [0.80](/filings/0001654954-25-009056.md) | [0.25](/filings/0001654954-25-013084.md) | not reported | [0.75](/filings/0001654954-26-004630.md) | [(0.75)](/filings/0001654954-26-007328.md) | [0.20](/filings/0001654954-25-013084.md) | not reported | [(0.02)](/filings/0001654954-26-004630.md) | [(0.07)](/filings/0001654954-26-007328.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [0.0](/filings/0001213900-23-082206.md) | [3.1](/filings/0001654954-25-002153.md) | [1.7](/filings/0001654954-24-006298.md) | [0.2](/filings/0001654954-24-010635.md) | [6.5](/filings/0001654954-24-014445.md) | [11.4](/filings/0001654954-26-001280.md) | [8.8](/filings/0001654954-25-005754.md) | [6.3](/filings/0001654954-25-009056.md) | [5.8](/filings/0001654954-25-013084.md) | [11.8](/filings/0001654954-26-007328.md) | [12.6](/filings/0001654954-26-004630.md) | [12.4](/filings/0001654954-26-007328.md) |
| Current assets | $m | [0.0](/filings/0001213900-23-082206.md) | [4.8](/filings/0001654954-25-002153.md) | [3.5](/filings/0001654954-24-006298.md) | [4.2](/filings/0001654954-24-010635.md) | [8.0](/filings/0001654954-24-014445.md) | [12.7](/filings/0001654954-26-001280.md) | [11.7](/filings/0001654954-25-005754.md) | [8.9](/filings/0001654954-25-009056.md) | [7.0](/filings/0001654954-25-013084.md) | [18.5](/filings/0001654954-26-007328.md) | [18.3](/filings/0001654954-26-004630.md) | [17.0](/filings/0001654954-26-007328.md) |
| Total assets | $m | [25.3](/filings/0001213900-23-082206.md) | [6.1](/filings/0001654954-25-002153.md) | [4.7](/filings/0001654954-24-006298.md) | [5.3](/filings/0001654954-24-010635.md) | [9.1](/filings/0001654954-24-014445.md) | [13.7](/filings/0001654954-26-001280.md) | [12.9](/filings/0001654954-25-005754.md) | [10.1](/filings/0001654954-25-009056.md) | [8.1](/filings/0001654954-25-013084.md) | [19.5](/filings/0001654954-26-007328.md) | [19.1](/filings/0001654954-26-004630.md) | [17.7](/filings/0001654954-26-007328.md) |
| Current liabilities | $m | [3.1](/filings/0001213900-23-082206.md) | [11.9](/filings/0001654954-25-002153.md) | [13.4](/filings/0001654954-24-006298.md) | [10.9](/filings/0001654954-24-010635.md) | [8.0](/filings/0001654954-24-014445.md) | [5.7](/filings/0001654954-26-001280.md) | [6.3](/filings/0001654954-25-005754.md) | [5.5](/filings/0001654954-25-009056.md) | [5.5](/filings/0001654954-25-013084.md) | [6.3](/filings/0001654954-26-007328.md) | [7.2](/filings/0001654954-26-004630.md) | [5.3](/filings/0001654954-26-007328.md) |
| Total liabilities | $m | [23.8](/filings/0001213900-23-082206.md) | [23.6](/filings/0001654954-25-002153.md) | [52.7](/filings/0001654954-24-006298.md) | [33.3](/filings/0001654954-24-010635.md) | [22.0](/filings/0001654954-24-014445.md) | [66.7](/filings/0001654954-26-001280.md) | [36.4](/filings/0001654954-25-005754.md) | [57.0](/filings/0001654954-25-009056.md) | [48.2](/filings/0001654954-25-013084.md) | [26.6](/filings/0001654954-26-007328.md) | [26.3](/filings/0001654954-26-004630.md) | [26.4](/filings/0001654954-26-007328.md) |
| Long-term debt | $m | not reported | [0.0](/filings/0001654954-24-004059.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [(12.2)](/filings/0001654954-24-014445.md) | [(17.5)](/filings/0001654954-26-001280.md) | [(48.1)](/filings/0001654954-25-013084.md) | [(28.0)](/filings/0001654954-25-013084.md) | [(12.9)](/filings/0001654954-25-013084.md) | [(53.0)](/filings/0001654954-26-007328.md) | [(23.5)](/filings/0001654954-26-007328.md) | [(46.9)](/filings/0001654954-26-007328.md) | [(40.1)](/filings/0001654954-25-013084.md) | [(7.1)](/filings/0001654954-26-007328.md) | [(7.2)](/filings/0001654954-26-007328.md) | [(8.6)](/filings/0001654954-26-007328.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(1,787) d](/filings/0001654954-24-014445.md) | [(767) d](/filings/0001654954-25-002153.md) | [(1,695)](/filings/0001654954-25-005754.md) | [(2,452) d](/filings/0001654954-25-009056.md) | [(251) d](/filings/0001654954-25-013084.md) | [(2,106) d](/filings/0001654954-26-001280.md) | [(2,098)](/filings/0001654954-26-004630.md) | [(1,821) d](/filings/0001654954-26-007328.md) | [(584) d](/filings/0001654954-25-013084.md) | [(3,502) d](/filings/0001654954-26-001280.md) | [814](/filings/0001654954-26-004630.md) | [(235) d](/filings/0001654954-26-007328.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities

## Shares

| Line item | Unit | Q1 FY2021 (2021-03-31) | Q1 FY2022 (2022-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [3.3](/filings/0001213900-22-025993.md) | [32.4](/filings/0001213900-22-025993.md) | [22.8](/filings/0001654954-24-010635.md) | [22.8](/filings/0001654954-24-014445.md) | [22.9](/filings/0001654954-25-005754.md) | [30.3](/filings/0001654954-25-009056.md) | [35.4](/filings/0001654954-25-013084.md) | [38.8](/filings/0001654954-26-004630.md) | [31.9](/filings/0001654954-26-007328.md) | [42.0](/filings/0001654954-25-013084.md) | [34.4](/filings/0001654954-26-004630.md) | [34.4](/filings/0001654954-26-007328.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 34,439,562 at 2026-08-06, from the cover of the [10-Q filed 2026-08-06](/filings/0001654954-26-007328.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.